Recommendation of the President – Remsima (infliximab)
On 28 February 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 23/2025 on the appraisal of Remsima (infliximab) as part of the B.33 drug program “Treatment of patients with active rheumatoid arthritis [RA] and juvenile idiopathic arthritis (ICD-10: M05, M06, M08)”